Volume 1, Issue 2
Company to Watch: Expression Pathology, Inc.

Expression Pathology, Inc. has now closed $850,000 of a $1.2 million Series A Preferred offering and is in due diligence with additional investors. EPI was chosen as the company 'Most Likely to Receive Funding' at Bio-Life-Tech Princeton.

For more information on Expression Pathology, Inc. please visit their website at www.expressionpathology.com.

Volume 1, Issue 2
February 12, 2007

ESE's Bio Life Tech conference provided an excellent opportunity to hone the company's message with great coaching and practice sessions, and good networking opportunities.

Casey Eitner
President & CEO
Expression Pathology




To remove your name from our mailing list, please click here.
Questions or comments? E-mail us at [email protected] or call (302) 777-2460.